Showing 2241-2250 of 3315 results for "".
- Hoya Vision Care Presents New Data on Myopia Management Spectacle Lenses at ARVOhttps://modernod.com/news/hoya-vision-care-presents-new-data-on-myopia-management-spectacle-lenses-at-arvo/2482800/Hoya Vision Care announced new clinical evidence from three key clinical studies highlighting the impact of 'Defocus Incorporated Multiple Segments (DIMS)' technology. The results were presented as part of the company’s 2025 scientific program, 'Exploring New Frontiers in Myopia
- Aurion Makes Leadership Announcementshttps://modernod.com/news/aurion-makes-leadership-announcements/2482757/Aurion Biotech announced the appointments of Edward J. Holland, MD, as Chief Medical Officer, and Eris P. Jordan, OD, as Chief Development Officer. Aurion is developing AURN001, an investigational, single-administration, allogeneic cell therapy for the treatment of corneal edema seconda
- Call for Nominations: Prevent Blindness Seeks to Honor Leaders in Vision Healthhttps://modernod.com/news/call-for-nominations-prevent-blindness-seeks-to-honor-leaders-in-vision-health/2482661/Prevent Blindness, one of the nation’s largest eye health and safety nonprofit organizations, issued their call for nominations for the “
- Prevent Blindness Receives Legacy Donation of $9.7 Million, Largest in Historyhttps://modernod.com/news/prevent-blindness-receives-legacy-donation-97-million-largest-in-history/2482622/Prevent Blindness announced it has received a donation of $9.7 million from the Estate of Pamela Behrens, a Florida resident and previous donor. Founded in 1908, this is the largest donation the organization has ever received. Ms. Behrens made the donation in honor of her late hus
- Aviceda Therapeutics Raises $207.5 Million to Advance Lead Program AVD-104 for Geographic Atrophy into Phase 3 Testinghttps://modernod.com/news/aviceda-therapeutics-raises-2075-million-to-advance-lead-program-avd-104-for-geographic-atrophy-into-phase-3-testing/2482603/Aviceda Therapeutics announced the closing of a $207.5 million Series C financing to propel the company’s pivotal phase 3 clinical trial for AVD-104, a treatment candidate for geographic atrophy
- BostonSight Publishes Study Highlighting Prose Lens Utilization for Drug Deliveryhttps://modernod.com/news/bostonsight-publishes-study-highlighting-prose-lens-utilization-for-drug-delivery/2482555/BostonSight announced it has published a study: “
- Alkeus Pharmaceuticals Announces Positive Results from SAGA Study of Gildeuretinol Acetate in GA Patientshttps://modernod.com/news/alkeus-pharmaceuticals-announces-positive-results-from-saga-study-of-gildeuretinol-acetate-in-ga-patients-3/2482445/Alkeus Pharmaceuticals announced results from the SAGA study, a phase 3 clinical trial of oral gildeuretinol acetate (ALK-001) in patients with geographic atrophy (GA) secondary to age-related macular degeneration (AMD). The study demonstrated a reduction in the growth rate of GA lesions by
- Aura Biosciences to Present Phase 2 Data on Belzupacap Sarotalocan for Choroidal Melanoma at Retina Society Annual Meetinghttps://modernod.com/news/aura-biosciences-to-present-phase-2-data-on-belzupacap-sarotalocan-for-choroidal-melanoma-at-retina-society-annual-meeting/2482412/Aura Biosciences announced that final data from its phase 2 study on the suprachoroidal administration of belzupacap sarotalocan (bel-sar) for treating small choroidal melanoma and indeterminate lesions will be presented at the Retina Society Annual Meeting. The event will take place from Septemb
- Safilo North America Appoints New Leaderhttps://modernod.com/news/safilo-north-america-appoints-new-leader/2482258/Safilo North America announced the appointment of Gabriele Cusani Sodano as president and chief commercial officer, effective April 2024. The company says Mr. Cusani brings a wealth of experience and a proven track record to succeed in this new role, which will focus on accelerating the implement
- False Claims Act Complaint Filed Against Regeneron for Fraudulent Drug Pricing Reportinghttps://modernod.com/news/false-claims-act-complaint-filed-against-regeneron-for-fraudulent-drug-pricing-reporting/2482228/The US Department of Justice (DOJ) has filed a complaint under the False Claims Act (FCA) against Regeneron alleging that the company fraudulently inflated Medicare reimbursement rates for Eylea (aflibercept) by knowingly submitting false average sales price reports to CMS that excluded